#ACR21 Abs#1196: Morning stiffness (MS) in pre-RA arthralgia associates w inflammation ⭐️Arthralgia pts: 14% ACPA+, 34% w MS MS correlates w ⬆️subclinical synovitis/tenosynovitis on MRI and higher CRP. Duration of morning stiffness correlates https://t.co/DUhgjbjQIr @Rheumnow https://t.co/dHl7LuY3ZA

We need to be better at identifying and managing #depression in patients with #axspa. In a group of 70 pts, many had high HADs-D & PHQ-9, with worse disease activity & #QoL compared to those with normal scores. Abs#1305 #ACR21 @RheumNow https://t.co/lNoo0HfMcC https://t.co/n7Vyl9L5FR

Ultrasound in CSA patients: Retro US cohort 110pts 28.2% w/ 💥Power Doppler synovitis. 36.8% at 6mo evolved to RA among which 100% PD+ vs 25% PD- PD + predicts evolution to clinical RA (OR 13.1; CI 1.07-161.04) Easier and less invasive than MRI! #Abstr1525 #ACR21 @RheumNow https://t.co/MkhWTvnv3L

TCZ in GCA: one disadvantage is that you can't use CRP+/- ESR for flares Mavrilimumab in GCA: - CRP/ESR consistently go up with symptomatic flares - CRP/ESR up less (cf. placebo), in the absence of Sx flares More signal, less noise. phase 2 post-hoc #ACR21 ABST1401 @RheumNow https://t.co/c0lMJMcQv0

Watch: Lupus Updates: Dr. Michelle Petri Dr. Michelle Petri offers perspective and insight into lupus related data presented Saturday at the #ACR21 annual meeting. https://t.co/L7T2mNJVH0 https://t.co/MCQ7nJjCIY

#ACR21 #Abstr1100 Pulmonary Hypertension is a rare complication of AOSD. What can we learn from case-series of N=13🧐 💠All were female 💠Severe at diagnosis: mean PAP 41mmHg; 85% had NYHA III&IV 💠38.5% mortality rate So, plz be aware of PAH @RheumNow https://t.co/gmXF3AzH2n https://t.co/s5CXrHYUor

Atypical patterns of HCQ retinopathy: - outside the central macula - missed by standard central macula screening - 41x more likely in Asians! Lesson: screening with extramacular SD-OCT for Asian HCQ pts is so, so important. 41x over. @MGHrheumatology #ACR21 ABST0989 @RheumNow https://t.co/0w7ALHJDSW

#ACR21 #Abstr1083 Do pts with Autoinflammatory disease flare differently during #COVID19? Survey of N=647 (mostly CAPS): 💠56% No change 💠Of pts who flared, 50% had low/absent fever 💠7% had COVID; mostly mild Shielding could influence results @RheumNow https://t.co/g7VazLfiT9 https://t.co/lzaSoMEzyR

#ACR21 #Abstr1011 Can we differentiate NEMO-deleted exon 5 autoinflammatory syndrome (NEMO-NDAS) vs CANDLE? Bioinformatics to mask the IKBKG pseudogene is promising and identified IL-6, 8,18, IFN-I and TNF-induced cell death as future targets @RheumNow https://t.co/tR2PNymMVn https://t.co/yCKHQx6R3E

Daniela Ospina Cardona presenting at the Down and Dirty 30 on VEXAS. Marked differences in mortality depending on exact mutation. Looking forward to hearing more about this at Plenary session III today #ACR21 @RheumNow https://t.co/R3gXpxOfSk

Baricitinib for *relapsing* GCA (Th1+Th17) w abbreviated steroid wean (15-22w) Despite being tougher to treat: 100% off steroids at 24w 93% off steroids at 52w no ischemic Sx promising as another GCA Rx option! (post-cessation 4pts flared) @MayoClinic #ACR21 ABST1396 @RheumNow https://t.co/dqFnHQYogk